07:00 , Jun 6, 2005 |  BC Week In Review  |  Company News

Australian Cancer Tech cancer news

ACU changed its name to Avantogen Ltd. The cancer company also is establishing headquarters in San Diego, Calif. Australian Cancer Technology Ltd. (ASX:ACU), Perth, Australia   Business: Cancer  ...
08:00 , Mar 28, 2005 |  BC Week In Review  |  Clinical News

Pentrys: Completed Phase IIb enrollment

ACU completed enrollment of 40 patients with hormone-refractory prostate cancer (HRPC) in an open-label, Australian Phase IIb trial. Australian Cancer Technology Ltd. (ASX:ACU), Perth, Australia   Product: Pentrys   Business: Cancer   Molecular target: Not...
08:00 , Mar 14, 2005 |  BC Week In Review  |  Company News

Australian Cancer Tech management update

Australian Cancer Technology Ltd. (ASX:ACU), Sydney, Australia   Business: Cancer   Hired: Leonard Firestone as CEO and a director, formerly president, CEO, CMO and a director of Manhattan Pharmaceuticals Inc. (MHTT); he replaces Paul Hopper,...
08:00 , Feb 28, 2005 |  BC Week In Review  |  Clinical News

GPI-0100: Phase I data

In a dose-escalation, U.S. Phase I trial in 42 evaluable patients with relapsed prostate cancer, GPI-0100 used in combination with a bivalent vaccine was well tolerated and led to a dose-dependent enhanced immune response. Bivalent...
08:00 , Feb 14, 2005 |  BC Week In Review  |  Clinical News

RP101: Phase I/II data

Data from an open-label, German Phase I/II trial in 13 patients showed that RP101 plus gemcitabine/cisplatin increased the 50% probability of survival by about an average of 15 months compared to a historic average of...
08:00 , Feb 7, 2005 |  BC Week In Review  |  Company News

Australian Cancer Tech board of directors update

Australian Cancer Technology Ltd. (ASX:ACU), Sydney, Australia   Business: Cancer   Resigned: Art Benvenuto  ...
08:00 , Dec 20, 2004 |  BC Week In Review  |  Clinical News

RP101: Started Phase II

The partners began an 8-month, double-blind, placebo-controlled, German Phase II trial in 22 patients with metastatic pancreatic cancer. The patients will receive RP101 tablets in combination with gemcitabine. Australian Cancer Technology Ltd. (ASX:ACU), Perth, Australia...
08:00 , Nov 22, 2004 |  BC Week In Review  |  Company News

Australian Cancer Tech board of directors update

Australian Cancer Technology Ltd. (ASX:ACU), Perth, Australia   Business: Cancer   Appointed: Richard Opara, a director, as non-executive chairman   Departed: Roger Aston as executive chairman, while remaining a director, chairman of the scientific advisory...
07:00 , Oct 4, 2004 |  BC Week In Review  |  Company News

Australian Cancer Tech, RESprotect deal

RESprotect granted ACU a North American license to RP101, a chemopotentiator that has completed a Phase I/II trial in metastatic breast, ovarian and pancreatic cancers, as well as small cell and non-small cell lung cancers....
07:00 , Aug 16, 2004 |  BC Week In Review  |  Company News

Australian Cancer Tech management update

Australian Cancer Technology Ltd. (ASX:ACU), Perth, Australia   Business: Cancer   Hired: Theresa Gerrard as director of clinical and regulatory affairs, while remaining president of TLG Consulting  ...